Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)-Reference-Cited by-同舟云学术

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

Published:2017-09-19 Issue:5 Volume:8 Page:1123-1134
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Awata Takuya^ORCID,Shimada Akira,Maruyama Taro,Oikawa Yoichi,Yasukawa Nobuyuki,Kurihara Susumu,Miyashita Yumi,Hatano Masako,Ikegami Yuichi,Matsuda Masafumi,Niwa Masataka,Kazama Youichiro,Tanaka Shoichiro,Kobayashi Tetsuro

Funder

Waksman Foundation of Japan

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-017-0299-7.pdf

Reference40 articles.

1. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes–considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38(6):979–88.

2. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16(5):780–8.

3. Tanaka S, Ohmori M, Awata T, et al. Diagnotic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the comitteeon slowly progressive insulin-dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6(1):1–7.